Introduction
HER-2/neu oncoprotein is a transmembrane receptor, belonging to the epidermal growth factor receptor (EGFR) family, with tyrosine kinase activity. HER-2/neu has been shown to be overexpressed, most commonly by gene amplification, in a number of human malignancies, including breast cancer (BRC). 1 Overexpression of the HER-2/neu oncoprotein in breast cancers is associated with shortened survival, enhanced aggressiveness, resistance to hormone-and chemotherapy [2] [3] [4] and, eventually, decreased sensitivity to therapy. 5 The extracellular domain of HER-2/neu is the target of trastuzumab (Herceptin ® ), the humanized anti-HER-2/neu monoclonal antibody. 6 It has also been proved that the anticancer efficacy of trastuzumab is highly dependent on the HER-2/neu amplification of breast cancer. 7 A careful selection of It is still a matter of debate whether HER-2/neu status should be evaluated by early testing with systematically performed examinations on the primary tumor at the time of diagnosis of early breast cancer, or by pretreatment testing, i.e. performed on either the primary tumor or a metastatic site at the time of tumor relapse. 9 To date, HER-2/neu status in the majority of cases is evaluated in the primary tumor, since routine biopsy of metastatic sites is not a standard procedure. 10 Nevertheless, the main targets of any systemic therapy in metastatic breast cancer are metastatic foci. 10 Current diagnostics is based on the assumption that the genotype of primary BRC is similar to the one found in the metastases. Meanwhile, experimental and some clinical data suggest that 1) the primary tumor is genetically heterogeneous, 2) the clones responsible for organ dissemination may not even be present in the primary tumor but develop through sequential genetic alterations, and 3) they compose a very small percentage of the primary tumor. 11 Earlier studies exclusively used HercepTest to assess the maintenance of HER-2/neu genotype in metastatic lesions and found it concordant in case of lymph node, liver and lung metastases. [12] [13] [14] [15] [16] Recent reports provided evidence that the HER-2/neu genotype of BRC may change in the metastases: loss of HER-2/neu expression was reported in one case in pleural metastases, 17 while loss of HER-2/neu amplification was found in 21%, but appearance of HER-2/neu amplification was even more frequent in visceral metastases (30%). 18 Our aim was to analyze the HER-2/neu status of bone metastasis compared to the primary tumor in a larger cohort of BRC cases.
Materials and Methods

Patients
Bone metastatic samples of breast cancer were retrospectively collected from the pathology divisions of the following institutes: Departments of Orthopedics and Traumatology of Semmelweis University, National Institute of Traumatology. Samples derived from open biopsies of bone metastases obtained during transfocal stabilization of impending, complete pathological fractures, or resection of bone metastases. We excluded 9 cases because of overdecalcination or insufficient amount of tumor tissue in the sections. In total we investigated 48 metastatic cases. We were able to obtain paraffin-embedded samples of the primary breast cancers in 23 cases. The characteristics of the patients are shown in Table 1 . We have assessed the histological grade of the metastases in 44 out of the 48 investigated cases by the BloomRichardson method as previously described. 19 
Determination of the HER-2/neu status
Immunohistochemistry (IHC). IHC was performed by using the HercepTest TM (DAKO, Glostrup, Denmark) according to the manufacturer's instruction, and as previously described. 20 The slides were reviewed by two investigators. HER-2/neu staining was assessed semiquantitatively on a scale from 0 (negative) to 3+ (strongly positive) according to standard protocols. 20 Fluorescence in situ hybridization (FISH) . FISH was performed in the cases where BRC had 2+ or 3+ HER-2/neu IHC status in the bone metastases and/or in the primary tumors, or if discordance was found in HER-2/neu status detected by IHC between primary tumors and their corresponding bone metastases. FISH was performed by using the Oncor INFORM system (Ventana) as previously described, 20 and by using the protocol No. 2 of the Benchmark automata stainer. Briefly, slides were deparaffinized and incubated with protease-3 for 10 minutes. After denaturation at 90 o C for 10 minutes, they were then incubated with one drop of INFORM HER-2/neu probe, followed by incubation with FITC/mouse anti-biotin and anti-mouse-Ig/FITC. In the next step slides were counterstained with 4,6-diamino-2-phenylindole (DAPI). Slides were assessed for HER-2/neu gene copy number as previously described: 20 for each specimen, gene copy level was assessed in two areas of at least 20 non-overlapping tumor cell nuclei by using an epifluorescence microscope (Nikon Eclipse-600). A tumor was considered to contain gene amplification if there were more than four copies of HER-2/neu per cell. 20 
Results
Of the 48 metastatic lesions 9 (18.75%) showed HER-2/neu overexpression by IHC (3+: 5, 2+: 4). We found HER-2/neu gene amplification in 1 out of the 4 IHC 2+ cases, and in 4 out of the 5 IHC 3+ cases (Table 2, Figure  1c,d) . In one of the IHC 3+ cases we were not able to confirm the gene amplification even after repeated analysis.
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LÔRINCZ et al Figure  1a,b) . In bone metastases of the 23 BRC we found only two cases where the HER-2/neu status was maintained while in two other cases the initial amplified status was changed to a HER-2/neu-negative one (Table 3) . Furthermore, we also detected a lower HER-2/neu gene copy number in the bone metastases of the HER-2/neu amplified BRC compared to the primary tumor (Figure 2) . On the other hand, we did not find alteration in the HER-2/neu status of the bone metastases of BRC where the primary tumor was normal ( Table 3) . 
Discussion
There are reports that the estrogen receptor (ER) status of BRC is different in the primary tumor and bone metastases: usually the initial ER-positive phenotype reverts to an ER-negative one. 21 A careful genetic analysis revealed a different cytogenetic profile of bone metastasis in BRC compared to the primary tumor. Furthermore, expression profiling also detected a unique gene signature in the bone metastases compared to other metastatic sites. 22 Bone is one of the most frequently involved sites during breast cancer progression. 23 It is, therefore, surprising that, with the exception of one study, 10 the HER-2/neu genotype of bone metastasis was analyzed only in a very small number of patients (<10). 18, 24, 25 These case reports documented a relatively frequent change in HER-2/neu genotype in distant metastases in up to 20% of the cases. These data suggested that the common dogma that BRC maintains the geno/phenotype in metastasis may not be valid. Our recent findings further support these notions, revealing that in a small proportion of cases (about 10%) the initial HER-2/neu genotype may change. This may not seem a significant proportion of BRC cases, but it must be considered that in our cohort studies 50% of cases with HER-2/neu amplification lost their genotype in bone metastases. Unfortunately we were not able to perform a larger study on bone metastases because in approximately half of our cases we were not able collect the primary samples for comparison. We suggest that in the subset of BRC cases with HER-2/neu amplification the conversion of the genotype may occur more frequently compared to cases without amplification, which maintained their genotype in our study. Previous analyses on the HER-2/neu status of BRC at various metastatic sites indicated that the original genotype may change, either due to the selection process during tumor progression or under the pressure of anti-HER-2/neu treatment. 12, [16] [17] [18] However, the switch in genotype does not necessarily occur at all metastatic sites. 17, 18 Since the therapy of the HER-2/neu-amplified and non-amplified metastatic BRC is different, based on our data and on the literature we suggest to perform HER-2/neu testing both on primary tumor and metastases, at least in the case of primary tumors with HER-2/neu amplification. When HER-2/neu status in metastatic BRC is negative at all locations tested, in other words, when there is no proof of maintained HER-2/neu amplification at any metastatic sites, there is no reason to apply anti-HER-2/neu therapy.
